These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24218513)

  • 1. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
    Iversen TZ; Engell-Noerregaard L; Ellebaek E; Andersen R; Larsen SK; Bjoern J; Zeyher C; Gouttefangeas C; Thomsen BM; Holm B; Thor Straten P; Mellemgaard A; Andersen MH; Svane IM
    Clin Cancer Res; 2014 Jan; 20(1):221-32. PubMed ID: 24218513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
    Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
    Front Immunol; 2018; 9():2145. PubMed ID: 30283461
    [No Abstract]   [Full Text] [Related]  

  • 4. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
    Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
    J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
    Wang W; Huang L; Jin JY; Jolly S; Zang Y; Wu H; Yan L; Pi W; Li L; Mellor AL; Kong FS
    Cancer Res; 2018 Feb; 78(3):809-816. PubMed ID: 29118088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
    Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
    Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
    Suzuki Y; Suda T; Furuhashi K; Suzuki M; Fujie M; Hahimoto D; Nakamura Y; Inui N; Nakamura H; Chida K
    Lung Cancer; 2010 Mar; 67(3):361-5. PubMed ID: 19487045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
    Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
    J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
    Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
    Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
    Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Jul; 25(19):2727-34. PubMed ID: 17602077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.
    Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W
    Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
    Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma.
    Engin A; Gonul II; Engin AB; Karamercan A; Sepici Dincel A; Dursun A
    World J Gastroenterol; 2016 Apr; 22(13):3592-601. PubMed ID: 27053851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indoleamine 2,3-dioxygenase activity during chemotherapy in patients with breast cancer].
    Sakurai K; Matsuo S; Enomoto K; Tani M; Kitajima A; Amano S
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):1991-3. PubMed ID: 20037301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation.
    Brandacher G; Cakar F; Winkler C; Schneeberger S; Obrist P; Bösmüller C; Werner-Felmayer G; Werner ER; Bonatti H; Margreiter R; Fuchs D
    Kidney Int; 2007 Jan; 71(1):60-7. PubMed ID: 17136028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
    Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
    Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
    Mandarano M; Orecchini E; Bellezza G; Vannucci J; Ludovini V; Baglivo S; Tofanetti FR; Chiari R; Loreti E; Puma F; Sidoni A; Belladonna ML
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoleamine 2,3-dioxygenase in lung allograft tolerance.
    Meloni F; Giuliano S; Solari N; Draghi P; Miserere S; Bardoni AM; Salvini R; Bini F; Fietta AM
    J Heart Lung Transplant; 2009 Nov; 28(11):1185-92. PubMed ID: 19783182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.
    de Jong RA; Nijman HW; Boezen HM; Volmer M; Ten Hoor KA; Krijnen J; van der Zee AG; Hollema H; Kema IP
    Int J Gynecol Cancer; 2011 Oct; 21(7):1320-7. PubMed ID: 21720257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.